BIG2-06 ALTTO

A randomised, multicentre, open label, phase III study of adjuvant lapatinib, trastuzumab, their sequence and their combination in patients with HER2+/ErbB2+ primary breast cancer.

Disease site: Breast cancer

Treatment Modality: Combination therapy

Status: In follow-up

Trial details

ALTTO is a Breast International Group (BIG) study with collaborative support provided by the ICR-CTSU. It is a randomised, open label multi-centre phase III study comparing the activity of lapatinib alone versus trastuzumab alone versus trastuzumab followed by lapatinib versus lapatinib concomitantly with trastuzumab in the adjuvant treatment of
patients with ErbB2 overexpressing and/or amplified breast cancer.

Chief Investigator: Professor Ian Smith (UK CI), Royal Marsden NHS Foundation Trust

ICR-CTSU Scientific Lead: Professor Judith Bliss

ISRCTN: N/A

Sponsor: GlaxoSmithKline

Funder: GlaxoSmithKline

Further information

Contact details and more information may be found on the ALTTO Trials homepage

ALTTO trials  listing on the UKCRN Portfolio

breast cancer cell
Major trial shows prolonged benefit of olaparib in early-stage inherited breast cancer

12/12/24

One year of treatment with the targeted drug olaparib improves long-term survival in women with high-risk, early-stage breast cancer with mutations in BRCA1 or BRCA2 genes, new results from a major clinical trial show.
See full story
Breast cancer cell spheroid blue and purple
New understanding of aggressive form of breast cancer paves the way for tests and treatments

10/12/24

Scientists have developed a machine learning tool that can predict how an aggressive type of breast cancer will respond to treatment, and when it will return.
See full story